...
首页> 外文期刊>International Journal of Pediatrics >What Limits Cardiac Performance during Exercise in Normal Subjects and in Healthy Fontan Patients?
【24h】

What Limits Cardiac Performance during Exercise in Normal Subjects and in Healthy Fontan Patients?

机译:什么限制了正常受试者和健康的Fontan患者在运动过程中的心脏表现?

获取原文
           

摘要

Exercise is an important determinant of health but is significantly reduced in the patient with a univentricular circulation. Normal exercise physiology mandates an increase in pulmonary artery pressures which places an increased work demand on the right ventricle (RV). In a biventricular circulation with pathological increases in pulmonary vascular resistance and/or reductions in RV function, exercise-induced augmentation of cardiac output is limited. Left ventricular preload reserve is dependent upon flow through the pulmonary circulation and this requires adequate RV performance. In the Fontan patient, the reasons for exercise intolerance are complex. In those patients with myocardial dysfunction or other pathologies of the circulatory components, it is likely that these abnormalities serve as a limitation to cardiac performance during exercise. However, in the healthy Fontan patient, it may be the absence of a sub-pulmonary pump which limits normal increases in pulmonary pressures, trans-pulmonary flow requirements and cardiac output. If so, performance will be exquisitely dependent on pulmonary vascular resistance. This provides a potential explanation as to why pulmonary vasodilators may improve exercise tolerance. As has recently been demonstrated, these agents may offer an important new treatment strategy which directly addresses the physiological limitations in the Fontan patient.
机译:运动是健康的重要决定因素,但在单心室循环的患者中运动会明显减少。正常的运动生理要求增加肺动脉压力,这会增加右心室(RV)的工作需求。在双心室循环中,随着肺血管阻力的病理性增加和/或RV功能降低,运动引起的心输出量增加受到限制。左心室的预紧力储备取决于通过肺循环的流量,这需要足够的RV性能。在Fontan患者中,运动不耐受的原因很复杂。在那些患有心肌功能障碍或其他循环系统病变的患者中,这些异常可能会限制运动中的心脏功能。但是,在健康的Fontan患者中,可能缺少次肺泵,从而限制了正常的肺压,经肺流量需求和心输出量。如果这样,性能将完全取决于肺血管阻力。这为为什么肺血管扩张剂可以改善运动耐量提供了可能的解释。如最近所证明的,这些药剂可提供重要的新治疗策略,其直接解决了丰坦患者的生理局限性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号